# Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

> **NCT06932263** · PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 540 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Tozorakimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06932263
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-26
- **Primary completion:** 2027-06-24
- **Final completion:** 2028-03-16
- **Target enrollment:** 540 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06932263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06932263, "Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06932263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*